Mode and Site of Action of Therapies Targeting Cgrp Signaling

Mode and Site of Action of Therapies Targeting Cgrp Signaling Publisher Pubmed

Labastidaramirez A¹ ; Caronna E^{2, 3} ; Gollion C⁴ ; Stanyer E^{1, 5} ; Dapkute A⁶ ; Braniste D^{7, 8} ; Naghshineh H⁹ ; Meksa L¹⁰ ; Chkhitunidze N¹¹ ; Gudadze T¹² ; Pozorosich P^{2, 3} ; Burstein R^{13, 14, 15} ; Hoffmann J^{1, 16}

Show Affiliations

1. Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, Kingâ€™s College London, London, SE1 1UL, United Kingdom
2. Headache Unit, Neurology Department, Vall dâ€™Hebron Universitary Hospital, Barcelona, Spain
3. Headache Research Group, Vall dâ€™Hebron Institut de Recerca, Universitat Autonoma de Barcelona, Barcelona, Spain
4. Department of Neurology, University Hospital of Toulouse, Toulouse, France
5. Nuffield Department of Clinical Neurosciences, Sleep and Circadian Neuroscience Institute, University of Oxford, Oxford, United Kingdom
6. Centre of Neurology, Vilnius University, Vilnius, Lithuania
7. Institute of Neurology and Neurosurgery, Diomid Gherman, Chisinau, Moldova
8. State University of Medicine and Pharmacy, Nicolae Testemitanu, Moldova
9. Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Science, Tehran, Iran
10. Headache Unit, Neurology and Neurosurgery Department, Riga East University Hospital Gailezers, Riga, Latvia
11. Department of Neurology, Caucasus Medical Centre, Tbilisi, Georgia
12. Department of Neurology, Christian Hospital Unna, Unna, Germany
13. Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States
14. Department of Anesthesia, Harvard Medical School, Boston, MA, United States
15. Center for Life Science, Room 649, 3 Blackfan Circle, Boston, 02215, MA, United States
16. NIHR-Wellcome Trust Kingâ€™s Clinical Research Facility/SLaM Biomedical Research Centre, Kingâ€™s College Hospital, London, United Kingdom

Source: Journal of Headache and Pain Published:2023

Abstract

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed. © 2023, Springer-Verlag Italia S.r.l., part of Springer Nature.

Related Docs

View other Related Docs

1. Immunologic Aspects of Migraine: A Review of Literature, Frontiers in Neurology (2022)

2. Future Targets for Migraine Treatment Beyond Cgrp, Journal of Headache and Pain (2023)

3. Glia Signaling and Brain Microenvironment in Migraine, Molecular Neurobiology (2023)

4. Different Pain States of Trigeminal Neuralgia Make Significant Changes in the Plasma Proteome and Some Biochemical Parameters: A Preliminary Cohort Study, Journal of Molecular Neuroscience (2018)

5. Cellular and Molecular Mechanisms Involved in the Analgesic Effects of Botulinum Neurotoxin: A Literature Review, Drug Development Research (2024)

6. The Effect of 17Β-Estradiol on Gene Expression of Calcitonin Gene-Related Peptide and Some Pro-Inflammatory Mediators in Peripheral Blood Mononuclear Cells From Patients With Pure Menstrual Migraine, Iranian Journal of Basic Medical Sciences (2015)

7. A Review: Fda-Approved Fluorine-Containing Small Molecules From 2015 to 2022, European Journal of Medicinal Chemistry (2023)

8. The Sense of Stopping Migraine Prophylaxis, Journal of Headache and Pain (2023)

Experts (# of related papers)

View all Related Experts

Ahmad Reza Dehpour (2)

Hossein Majedi Ardekani (1)

Style	Citing Format
MLA	Labastidaramirez A, et al.. "Mode and Site of Action of Therapies Targeting Cgrp Signaling." Journal of Headache and Pain, vol. 24, no. 1, 2023, pp. -.
APA	Labastidaramirez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, Naghshineh H, Meksa L, Chkhitunidze N, Gudadze T, Pozorosich P, Burstein R, Hoffmann J (2023). Mode and Site of Action of Therapies Targeting Cgrp Signaling. Journal of Headache and Pain, 24(1), -.
Chicago	Labastidaramirez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, Naghshineh H, et al.. "Mode and Site of Action of Therapies Targeting Cgrp Signaling." Journal of Headache and Pain 24, no. 1 (2023): -.
Harvard	Labastidaramirez A et al. (2023) 'Mode and Site of Action of Therapies Targeting Cgrp Signaling', Journal of Headache and Pain, 24(1), pp. -.
Vancouver	Labastidaramirez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, et al.. Mode and Site of Action of Therapies Targeting Cgrp Signaling. Journal of Headache and Pain. 2023;24(1):-.
BibTex	@article{ author = {Labastidaramirez A and Caronna E and Gollion C and Stanyer E and Dapkute A and Braniste D and Naghshineh H and Meksa L and Chkhitunidze N and Gudadze T and Pozorosich P and Burstein R and Hoffmann J}, title = {Mode and Site of Action of Therapies Targeting Cgrp Signaling}, journal = {Journal of Headache and Pain}, volume = {24}, number = {1}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Labastidaramirez A AU - Caronna E AU - Gollion C AU - Stanyer E AU - Dapkute A AU - Braniste D AU - Naghshineh H AU - Meksa L AU - Chkhitunidze N AU - Gudadze T AU - Pozorosich P AU - Burstein R AU - Hoffmann J TI - Mode and Site of Action of Therapies Targeting Cgrp Signaling JO - Journal of Headache and Pain VL - 24 IS - 1 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract